CSO

EQS-News: Passing of the baton at init SE’s Managing Board

Retrieved on: 
Wednesday, April 10, 2024
EUR, Growth, Supervisory board, Transport, Knowledge, Transport for London, History, CSO, USD, Airline

There will be a change to the Managing Board of init innovation in traffic systems SE (ISIN DE 0005759807) on 1 October 2024.

Key Points: 
  • There will be a change to the Managing Board of init innovation in traffic systems SE (ISIN DE 0005759807) on 1 October 2024.
  • Dr. Jürgen Greschner (62), the long-serving CSO has expressed his desire to step down from the Managing Board on this date.
  • As the sole managing director, he built up INIT Innovations in Transportation Inc. in the United States, back in 1999.
  • In addition, Jürgen Greschner has been the Deputy Chairman of the Managing Board of init SE since 2015.

EQS-News: Nordex Group receives 98 MW order from Sweden

Retrieved on: 
Wednesday, April 10, 2024
Energi, Electricity, Wind, Cold climate, CSO, Farm, Renewable energy

The Nordex Group has received an order from Holmen Energi AB for 98 MW in Sweden.

Key Points: 
  • The Nordex Group has received an order from Holmen Energi AB for 98 MW in Sweden.
  • In summer 2025, the Nordex Group will supply and install 14 N163/6.X turbines for the Blisterliden wind farm in a forested area in the county of Västerbotten in the Northern of Sweden.
  • Patxi Landa, CSO of the Nordex Group: "We look forward to Holmen’s first project with Nordex.
  • Blisterliden is Holmen Group’s first project with the Nordex Group.

EQS-News: Nordex Group receives 264 MW order from Lithuania

Retrieved on: 
Wednesday, April 10, 2024
Wind, Achema, CSO, Renewable energy

UAB Renerga, the leading developer of wind energy projects in Lithuania and a company of the Achema Group, contracted the Nordex Group to supply 40 N163/6.X turbines.

Key Points: 
  • UAB Renerga, the leading developer of wind energy projects in Lithuania and a company of the Achema Group, contracted the Nordex Group to supply 40 N163/6.X turbines.
  • The Delta4000 series turbines are projected for the 264 MW Pagegiai wind farm project in the west of the country.
  • Lidija Lubiene, Chairman of the Board of the Achema Group: “Renerga is the founder of renewable energy in Lithuania.
  • We see the supply contract as the starting point of a powerful cooperation between both groups.”
    Including this new order, as of today the Nordex Group has sold more than 850 MW since 2015 in Lithuania.

EQS-News: Epigenomics AG publishes financial results for fiscal year 2023

Retrieved on: 
Wednesday, April 10, 2024
EUR, Supervisory board, AG, Research, Sale, ECX, HGB, Epigenomics AG, Bank statement, News, Investment, Patent, CSO, Commercial code, Lithium

Berlin (Germany), March 14, 2024 – Epigenomics AG (FSE: ECX, the “Company”) today reported financial results (according to HGB) for fiscal year 2023.

Key Points: 
  • Berlin (Germany), March 14, 2024 – Epigenomics AG (FSE: ECX, the “Company”) today reported financial results (according to HGB) for fiscal year 2023.
  • In July 2023, Epigenomics AG entered into an agreement with New Day Diagnostics LLC for the sale of substantially all of its assets, which was approved by the Extraordinary General Meeting in September 2023 and closed in October 2023.
  • Based on the measures taken, Epigenomics AG expects that the available financial resources will be sufficient until 2026.
  • The annual financial statements for the 2023 fiscal year can be found on the Epigenomics website at: https://www.epigenomics.com/news-investors/financial-reports/ .

EQS-News: ActiTrexx treats first patient with novel regulatory T cell therapy against Graft-versus-Host Disease

Retrieved on: 
Wednesday, April 10, 2024
Cell, Bone marrow, Disease, Transplant, Risk, Clinic, Patient, Gastrointestinal tract, Mortality, Haematopoietic system, Leukemia, Quality of life, Graft-versus-host disease, Clinical trial, Skin, Safety, CSO, Liver, Acute leukemia, Vaccine

GvHD is a severe and potentially life-threatening complication that can arise after an allogeneic haematopoietic stem cell transplantation and affects about 50 % of recipients.

Key Points: 
  • GvHD is a severe and potentially life-threatening complication that can arise after an allogeneic haematopoietic stem cell transplantation and affects about 50 % of recipients.
  • GvHD occurs when the stem cell donor’s T cells attack the patient’s tissues, leading to a range of symptoms that can affect the skin, gastrointestinal tract, and liver.
  • Prof. Dr. Andrea Tüttenberg, CEO of ActiTrexx, said: “GvHD can lead to life-long symptoms for the patient and is a major cause for the high mortality rate of blood stem cell transplantation.
  • Ten patients who have recently received a blood stem cell transplantation as treatment for leukemia will receive a single treatment with Actileucel.

EQS-News: CRS initiates new chapter by appointing leading industry expert Elisabeth Lackner as Chief Executive Officer

Retrieved on: 
Wednesday, April 10, 2024
University, Growth, Vineta, Patient, Knowledge, Element, CRS, Doctor of Philosophy, Contract research organization, QP, Investment, Qualified person (European Union), CSO, Management

Mannheim, Germany, March 15, 2024 – CRS Clinical Research Services, an expert early-phase Contract Research Organization (CRO), today announced the appointment of Dr. Elisabeth Lackner as Chief Executive Officer (CEO), effective today.

Key Points: 
  • Mannheim, Germany, March 15, 2024 – CRS Clinical Research Services, an expert early-phase Contract Research Organization (CRO), today announced the appointment of Dr. Elisabeth Lackner as Chief Executive Officer (CEO), effective today.
  • Dr. Elisabeth Lackner, CEO of CRS, commented: “I am honoured to join this great management team and to guide the organization into its next chapter of strategic growth and innovation.
  • “Together, we aim to propel CRS to new heights, centred on internationalization, strategic expansion, and a relentless pursuit of excellence."
  • Dr. Lackner is a highly experienced and well-respected global thought leader with over 20 years of experience in the healthcare industry.

EQS-News: Nordex Group receives orders for 295 MW from EDF Renewables in South Africa

Retrieved on: 
Wednesday, April 10, 2024
Wind, Nordex, Coal, CSO, Hartebeesthoek Radio Astronomy Observatory, Farm, EDF Renewables, EDF, Renewable energy

End of March, EDF Renewables (South Africa) a subsidiary of EDF Renouveables and Electricité de France (EDF), placed orders with the Nordex Group for two wind energy projects in South Africa.

Key Points: 
  • End of March, EDF Renewables (South Africa) a subsidiary of EDF Renouveables and Electricité de France (EDF), placed orders with the Nordex Group for two wind energy projects in South Africa.
  • The Korosun 2 cluster, consisting of the Umsobomvu  and Hartebeesthoek projects, will comprise 50 N163/5.X turbines with a total capacity of 295 MW.
  • The Nordex Group will also be responsible for the maintenance and servicing of the turbines for a period of 20 years.
  • The Nordex Group is installing the N163/5.X turbines on tubular steel towers with a hub height of 118 metres.

Cambridge Isotope Laboratories, Inc. (CIL) Announces Relocation of Corporate Headquarters and Expansion of Research & Development and cGMP Production

Retrieved on: 
Friday, March 15, 2024
CIL, GMP, CSO, QC, CGMP, Isotope, Research, Growth, API, Fine chemical

The new location is a two-building, 150,000-square-foot campus with 25 lakefront acres at 100 & 200 Ames Pond Drive.

Key Points: 
  • The new location is a two-building, 150,000-square-foot campus with 25 lakefront acres at 100 & 200 Ames Pond Drive.
  • The Ames Pond campus will be the home of a new 8,000-square-foot research and development (R&D) facility and will significantly expand cGMP, QC, formulations, and production labs.
  • This expansion provides CIL the space to develop new products and invest in advanced analytical and production technologies," states CIL's Chief Science Officer (CSO) Todd Osiek.
  • CIL will continue operating its existing headquarters at 3 Highwood Drive, Tewksbury, MA, and production facility located 50 Frontage Road in Andover, MA.

AskBio Names Mansuo Shannon Chief Scientific Officer

Retrieved on: 
Tuesday, April 9, 2024
Eli Lilly, Alzheimer's disease, Gene editing, Princeton University, MIT, Research, Bayer, Chugai Pharmaceutical Co., Doctor of Philosophy, Samulski, Therapy, Eli Lilly and Company, CSO, Molecular biology, Management

Shannon joins AskBio from Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company

Key Points: 
  • Shannon joins AskBio from Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company
    Co-Founder and former Chief Scientific Officer R. Jude Samulski to remain member of AskBio Board of Directors
    Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, announced today that on April 8, 2024, Mansuo Shannon, PhD, was named the company’s next Chief Scientific Officer (CSO).
  • Shannon joins AskBio from Prevail Therapeutics, where she also served as CSO.
  • Reporting to Gustavo Pesquin, Chief Executive Officer (CEO), Shannon will be a member of AskBio’s Executive Leadership Team and head its R&D organization.
  • As part of her role as CSO at AskBio, Shannon will develop and implement the company’s future R&D strategy.

BullFrog AI’s CSO, Tom Chittenden, to Present at the Quantum Computing Symposium at Bio-IT World Conference & Expo

Retrieved on: 
Tuesday, April 9, 2024
Organization, Conference, Drug discovery, COVID-19, Patient, Research, Artificial intelligence, Classification, Personalized medicine, Medicine, Quantum, Bullfrog, Machine learning, CSO

The presentation, titled "Quantum Assisted AI/ML for Precision Medicine," is scheduled for 1 pm ET.

Key Points: 
  • The presentation, titled "Quantum Assisted AI/ML for Precision Medicine," is scheduled for 1 pm ET.
  • Chittenden's presentation will explain how quantum methods have been used to decipher complex disease patterns, including analysis of multi-omics cancer data and classification of severe COVID-19 patients.
  • "The research I will highlight during my presentation is a testament to the synergies between quantum computing and machine learning, offering novel solutions to longstanding challenges in biomedical sciences."
  • The Quantum Computing Symposium is a premier event for professionals in the pharmaceutical industry, highlighting the revolutionary role of quantum technologies across various sectors, including drug discovery and supply chain management.